Enterprise value to EBIT forward of MEDIFAST INC – NYSE:MED
The article focuses on the "Enterprise value to EBIT forward" metric for MEDIFAST INC (NYSE: MED). It presents this financial data point within the context of TradingView's platform, indicating that the information is related to the company's financial performance.
Medifast Inc focus on weight-loss programs as industry shifts
Medifast Inc is adapting its weight-loss and nutrition programs in response to changing consumer demands and the rise of pharmacological treatments for obesity. The company emphasizes structured meal plans, coaching, and long-term behavior change, balancing simplicity with flexibility in its offerings. Medifast faces competition from various wellness platforms and must navigate regulatory scrutiny while attracting and retaining customers through effective marketing and product innovation.
Medifast, Inc.(NYSE: MED) dropped from Russell 2000 Value Benchmark
Medifast, Inc. (NYSE: MED) has been removed from the Russell 2000 Value Benchmark. The company, a health and wellness firm known for its OPTAVIA brand, announced this development on June 29, 2026, and also recently appointed Nicholas Johnson as its new CEO. The article includes recent leadership changes and earnings call information, alongside general company and financial data.
Price to sales forward of MEDIFAST INC – NYSE:MED
This article provides a brief overview of the "Price to sales forward" metric for MEDIFAST INC (NYSE: MED) on TradingView. It indicates that the market is closed with no trades and lists the company's financial information, news, and other data available on the platform. The content primarily focuses on the display of this specific financial metric within the TradingView interface.
Price to earnings forward of Medifast, Inc. – BMV:MED
This article provides financial information for Medifast, Inc. (BMV:MED) specifically focusing on its forward price-to-earnings ratio. It presents a table with details on the period, value, and change for this financial metric, indicating that the data is made by humans. The content is hosted on TradingView, a financial charting and analysis platform.
OPTAVIA Essential 1 Bar from Medifast Inc. - portion-controlled fuel for busy investors
The article highlights the OPTAVIA Essential 1 Bar from Medifast Inc. as a portion-controlled meal replacement integral to the OPTAVIA weight management program. It details the bar's design for fixed "Fueling" units, its role in a coach-supported system, and its impact on Medifast's recurring revenue model and stock value (MED, US58470S1024). The piece also discusses the product's strengths in predictability, trade-offs in flexibility, and its availability primarily through OPTAVIA's e-commerce platform.
Enterprise value to EBIT forward of Medifast, Inc. – BMV:MED
This article focuses on the enterprise value to EBIT forward of Medifast, Inc. (BMV:MED). It is a financial snapshot provided by TradingView, detailing a specific financial metric for the company's stock performance. The content includes market data and references from FactSet and the American Bankers Association.
Medifast, Inc. Actuals & Estimates (BMV:MED)
This article provides an overview of Medifast, Inc. (BMV:MED) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, actual earnings, revenue data, and employee numbers, alongside analyst opinions and future forecasts for the stock.
Enterprise value to EBITDA forward of MEDIFAST INC – NYSE:MED
This article displays the "Enterprise value to EBITDA forward" for MEDIFAST INC, traded on the NYSE under the symbol MED. It shows the period, value, change, and percentage change. The data is provided by FactSet Research Systems Inc.
Medifast, Inc. Actuals & Estimates (BOATS:MED)
This article provides an overview of Medifast, Inc. (BOATS:MED) stock, including financial actuals and analyst estimates. It covers details such as earnings, revenue, net income, EBITDA, employee count, historical stock prices, and future earnings report dates. The content aims to help investors analyze the company's financial health and market performance.
Price to book forward of Medifast, Inc. – BIVA:MED
This article provides key financial information for Medifast, Inc. (BIVA:MED), specifically focusing on its price to book forward ratio. It highlights that the market is currently closed with no trades, and offers a brief overview of the company's financials, news, community, and forecasts through TradingView.
Medifast, Inc. Actuals & Estimates (NYSE:MED)
This article provides an overview of Medifast, Inc. (NYSE: MED) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, discusses earnings reports, revenue, net income, market capitalization, volatility, and employee count, and guides on how to trade the stock.
Price to sales forward of Medifast, Inc. – BIVA:MED
This article provides access to the "Price to sales forward" financial data for Medifast, Inc. (MED) on the BIVA exchange through TradingView. It highlights the availability of financial metrics, news, community insights, and forecasts for the company. The content primarily acts as a gateway to financial information and tools offered by TradingView and its partners.
MED Forecast — Price Target — Prediction for 2027
This article provides a forecast for Medifast, Inc. (MED) stock, including a price target of 210.34 MXN based on one analyst's opinion. It details the company's financial performance, such as recent earnings and revenue, and offers various stock metrics like market capitalization and volatility. Additionally, it addresses frequently asked questions about MED's stock price, ticker, historical highs and lows, and upcoming earnings reports.
Medifast Inc (MED) Financial Health: Profitability & Balance Sheet Analysis
Medifast Inc (MED) currently holds a financial score of 7.16, placing it 51st out of 94 companies in the Food & Tobacco industry, indicating robust financial health despite average operating efficiency. The company reported a significant year-over-year decrease in its latest quarterly revenue by 34.29% and a decrease in net profit by 174.87%. While its financial status is strong, key financial metrics related to cash, assets, liabilities, and free cash flow have not been fully disclosed, impacting detailed evaluations of its quality of earnings, operational efficiency, growth potential, and shareholder returns.
Why the Essential 1 Month Kit from Medifast quietly fits busy routines
The article highlights Medifast's Essential 1 Month Kit, designed to integrate seamlessly into busy routines by offering a structured, portion-controlled weight management plan. It emphasizes the convenience and predictability of the kit, which includes pre-measured meal replacements like shakes, bars, and soups, eliminating the need for calorie counting or extensive meal prep. While offering excellent structure for individuals seeking clear rules and visible progress, the kit's main limitation is its lack of flexibility for those who prefer culinary spontaneity or frequent dining out.
Medifast Stock - Analyst expectations and business outlook
Medifast (MED) is under investor scrutiny as analysts reassess its performance against a changing weight-management market, especially with the rise of GLP-1 drugs. The company is transitioning from a coach-centric weight-loss model to a broader health and wellness strategy, a move analysts are closely watching for its impact on revenue and margins. Key focuses include customer retention, coach engagement, and the effectiveness of its expanded value proposition.
Medifast Inc (MED) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Medifast Inc (MED), highlighting its major institutional shareholders and a breakdown of shareholder types. It provides data on institutional shareholding trends over several quarters and lists recent shareholder activity by key firms. The information is current as of May 10th for general shareholder stats and April 1st for institutional shareholding, with some individual firm activities updated more recently.
Medifast Inc (MED) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Medifast Inc (MED), noting that relevant data for FY2025, FY2025Q4, FY2025Q2, FY2025Q1, and FY2024 by business segment has not yet been disclosed by the company. It indicates that the United States contributed $385.79 million to Medifast's revenue, with its proportion currently at 0.00%. The article primarily serves as a placeholder for Medifast's financial segment and regional revenue data.
Medifast Inc (MED) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Medifast Inc (MED), highlighting its current risk score and ranking within the Food & Tobacco industry. Key metrics such as beta value, VaR (Value at Risk), maximum drawdown, volatility, and liquidity are detailed. The report also notes the neutral impact of the U.S. Dollar Index on the domestic-focused industry.
Medifast Inc (MED) Institutional Confidence
Medifast Inc's institutional confidence score is 7.00, placing it 24th out of 95 in the Food & Tobacco industry. The institutional shareholding proportion decreased by 2.48% quarter-over-quarter to 83.21%. James Simons is the largest institutional shareholder, holding 7.55% of shares outstanding.
Medifast Inc (MED) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Medifast Inc (MED), highlighting its stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. While the stock's current price momentum score is 5.30, trading between resistance at $12.61 and support at $10.57, the overall signal from indicators and moving averages leans towards a "Sell" recommendation. The analysis notes 2 sell signals from technical indicators and 5 sell signals from moving averages against 1 buy signal.
New coaching twist, Medifast’s OPTAVIA app deepens its weight-loss ecosystem
Medifast's OPTAVIA app is strengthening its digital presence by integrating personalized meal plans, progress tracking, and direct access to coaches, aiming to enhance user engagement. The app supports the company's structured weight-loss programs and the "Habits of Health Transformational System," providing tools for diet, mindset, and movement. By connecting clients to coaches and simplifying order management, Medifast hopes to improve retention and maintain its competitive edge in the weight management market.
What Science-Backed Subscription Health Programs Measure Differently
This article discusses how science-backed subscription health programs distinguish themselves by providing specific, verifiable measurements beyond simple scale weight. It highlights OPTAVIA's approach, which uses peer-reviewed randomized controlled trials and clinical gold-standard body composition assessments like DXA scanning to demonstrate results, including significant lean mass retention and fat loss. The piece emphasizes the importance of thorough measurement tools, high study completion rates, and clear interpretation of terms like "science-backed" for consumers evaluating health programs in a growing market.
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
The article discusses the impact of perimenopause and menopause on metabolic health and weight management, highlighting how declining estrogen accelerates visceral fat accumulation and lean muscle loss. It emphasizes that traditional weight loss methods focusing solely on scale weight are ineffective during this period. The article promotes OPTAVIA's clinically supported programs, which target visceral fat reduction and lean mass preservation, alongside the benefits of coaching for better outcomes.
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
The article discusses the metabolic challenges women face during perimenopause and menopause, emphasizing that standard weight management approaches often fail to address accelerated visceral fat accumulation and lean muscle loss. It highlights OPTA VIA's clinically supported programs, which focus on reducing visceral fat while preserving lean mass, and stresses the importance of coaching during these hormonal transitions. The piece explains why body composition metrics are more crucial than scale weight for women over 40 and outlines what a metabolically appropriate program entails.
What Science-Backed Subscription Health Programs Measure Differently
This article examines what differentiates truly science-backed subscription health programs in the $31 billion weight loss and weight management market. It highlights that terms like "clinically studied" lack standardized definitions, emphasizing the importance of specific measurement tools like DXA scanning over simple scale weight, and high study completion rates in verifying program outcomes. OPTAVIA is presented as an example of a program that utilizes peer-reviewed randomized controlled trials and DXA body composition assessment to demonstrate its effectiveness, including significant lean mass retention and fat loss.
Medifast Announces Chief Legal Officer Resignation and Transition
Medifast (MED) announced that its Chief Legal Officer and Corporate Secretary, Jason L. Groves, Esq., resigned on May 29, 2026, and entered into a separation agreement. The company stated his departure was not due to disagreements or operational issues and has initiated a search for a permanent replacement. Analysts currently rate MED stock as a Hold with a $12.00 price target.
Medifast chief legal officer Jason Groves resigns; company begins search for successor
Medifast (NYSE: MED) announced the resignation of its Chief Legal Officer and Corporate Secretary, Jason L. Groves, effective Thursday. Groves will receive a one-time severance payment. The company has begun the search for his replacement, noting that his departure was not due to any disagreement with Medifast's operations or policies.
[8-K] MEDIFAST INC Reports Material Event
MEDIFAST INC (MED) has filed an 8-K report announcing the resignation of Jason L. Groves, Esq., Chief Legal Officer & Corporate Secretary, effective May 29, 2026. He will receive a one-time severance payment equal to one month of his annual base salary. The company stated his departure was not due to any disagreements and it has begun searching for a replacement.
Medifast (MED) director takes equity awards instead of cash for board service
Medifast director Jeffrey Matthew Rose has opted to receive equity awards instead of cash compensation for his board service. He received two grants of common stock on May 26, 2026, totaling 18,419 shares and 11,680 shares, respectively, classified as awards with no cash price per share. These transactions were made under Medifast’s Director's Deferred Compensation Plan and Amended and Restated 2012 Share Incentive Plan, with the restricted stock units set to vest on May 26, 2027.
Cash-settled RSU grant boosts Medifast (MED) director derivative holdings
Medifast director Xian Ming received an annual grant of 11,680 cash-settled restricted stock units under the 2012 Share Incentive Plan. These units, which vest in full on May 26, 2027, represent a right to receive the cash value of one share of common stock upon vesting. This grant increases Ming's total reported derivative holdings tied to common stock to 43,822.918 units and is considered a compensation award rather than an open-market transaction.
Medifast Inc (NYSE: MED) director Jeffrey Rose files routine Form 3
Medifast Inc. director Jeffrey Rose has filed a routine Form 3, an initial statement of beneficial ownership. This filing indicates he is a director of the company but reports no stock transactions or current share holdings, serving as a standard disclosure to establish his insider status for future reporting requirements. The Form 3 confirms his role as a director and outlines the regulatory requirements for such filings.
Medifast (NYSE: MED) director Kiai Parsa takes equity grants in lieu of cash fees
Medifast director Kiai Parsa received equity grants, comprising 7,637 restricted stock units and 11,680 shares of common stock, on May 26, 2026, as compensation for his annual director fees, rather than cash. These awards, granted under the company's Director's Deferred Compensation Plan and Share Incentive Plan, will vest in full on May 26, 2027. This transaction represents compensation and not an open-market purchase or sale.
Medifast (MED) director receives 11,680 RSUs as annual fee compensation
Medifast (MED) director Andrea B. Thomas was granted 11,680 restricted stock units (RSUs) as part of her annual director fees through the company's Director's Deferred Compensation Plan. These RSUs, which represent shares of common stock, will vest in full on May 26, 2027. Following this grant, Thomas directly holds 35,697.123 shares of Medifast common stock.
Medifast (NYSE: MED) director awarded 11,680 restricted stock units in fee grant
Elizabeth A. Geary, a director at Medifast Inc. (NYSE: MED), was granted 11,680 restricted stock units (RSUs) as part of her annual director fees. These RSUs, valued at $0.00 per share, will vest in full on May 26, 2027, and reflect compensation rather than an open-market purchase. Following this grant, Geary's direct common stock holdings in Medifast total 31,225 shares.
What is Zacks Research's Forecast for Medifast Q2 Earnings?
Zacks Research has updated its Q2 2026 EPS forecast for Medifast (NYSE:MED) to a loss of $0.68 per share, a more cautious outlook than their previous estimate. Despite Medifast beating Q1 expectations, analysts maintain a "Reduce" rating with an average target price of $12.00, though recent insider buying suggests some confidence in the stock. The article also details recent institutional trading activity and updated insider transactions for Medifast.
Medifast Appoints Nicholas Johnson as New CEO and Amends 2012 Share Incentive Plan
Medifast, Inc. announced Nicholas Johnson as its new CEO, effective June 8, 2026, succeeding Daniel R. Chard. Shareholders also approved an amendment to the 2012 Share Incentive Plan, increasing authorized shares by 250,000 to attract and retain key personnel. These changes were part of the 2026 Annual Meeting outcomes, which also saw the re-election of all director nominees and ratification of the independent auditor.
Medifast Taps Johnson to Succeed Chard as CEO
Medifast has announced that Johnson will succeed Chard as CEO. The article also briefly mentions Unity Software's fourth-quarter financial results, reporting a 35% year-over-year revenue increase to $609 million, though the company recorded a loss of 66 cents per share.
Medifast Names Nicholas Johnson as CEO
Medifast has appointed Nicholas Johnson as its new Chief Executive Officer. Johnson will focus on driving company growth and innovation in the health and wellness sector. His leadership is expected to bring a fresh perspective to Medifast's strategic initiatives.
Medifast names Nicholas Johnson as CEO effective June 1
Medifast Inc. has appointed Nicholas Johnson as its new CEO, effective June 1, 2026, succeeding Dan Chard who will remain Chairman. Johnson, previously the company's President, takes over amidst financial challenges including a 36% revenue decline and a reported loss per share. Despite these headwinds, the stock has gained 17.9% year-to-date and appears undervalued according to InvestingPro data.
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer
Medifast, Inc. announced the formal appointment of Nicholas Johnson as its new Chief Executive Officer, effective June 1, 2026. Johnson, who previously served as President, will succeed Dan Chard, who will remain as Chairman of the Board. This appointment follows the company's leadership transition plan disclosed in January, highlighting Johnson's role in Medifast's transformation into a metabolic health company.
Medifast names Nicholas Johnson as CEO effective June 1 By Investing.com
Medifast Inc. announced that Nicholas Johnson will become its new CEO, effective June 1, 2026, succeeding Dan Chard who will remain Chairman. Johnson, previously President, takes the helm during a period of financial challenges for the company, including a significant revenue decline and a per-share loss, though it maintains strong gross profit margins. Despite these hurdles, Medifast's stock has shown resilience and appears undervalued according to InvestingPro analysis.
Medifast names Nicholas Johnson as CEO effective June 1 By Investing.com
Medifast Inc. (NYSE:MED) has appointed Nicholas Johnson as its new Chief Executive Officer, effective June 1, 2026, succeeding Dan Chard who will remain Chairman. Johnson, who previously served as company President, takes leadership amidst financial challenges including a 36% revenue decline and a net loss, though analysts note strong gross profit margins. Despite these headwinds, Medifast's stock has seen a 17.9% gain year-to-date and is considered undervalued by InvestingPro.
Nicholas Johnson becomes Medifast (NYSE: MED) CEO as investors back equity plan
Medifast, Inc. announced the appointment of Nicholas Johnson as its new Chief Executive Officer, succeeding Dan Chard who transitions to non-executive Chairman. Stockholders also approved an amendment to the 2012 Share Incentive Plan, authorizing an additional 250,000 shares for equity awards. Johnson's compensation package includes a $600,000 base salary and significant bonus and long-term incentive targets, reflecting a 69% increase over his previous role as President.
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
OPTAVIA's coaching model emphasizes human support in weight management, citing research that shows coach-supported clients achieve significantly better weight loss and retention rates compared to self-directed programs. The company highlights that its coaches provide program guidance, accountability, and emotional support, differentiating their approach from automated solutions. This model aims to address high dropout rates in weight management by fostering sustained behavior change through personalized interaction.
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
This article examines the effectiveness of weight loss coaching versus app-only programs, concluding that human support and accountability lead to significantly better long-term outcomes. It highlights research demonstrating that individuals with coaches achieve greater weight and fat loss, along with improved body composition. The piece stresses the importance of evidence-based program evaluation, focusing on outcomes beyond just scale weight, such as visceral fat reduction and lean mass preservation.
Medifast reconfirms $270M-$300M 2026 revenue outlook as it targets profitability improvements starting in Q4 2026
Medifast (NYSE: MED) reconfirmed its 2026 revenue outlook in the range of $270 million to $300 million. The company expects improvements in profitability to begin in Q4 2026. This announcement highlights Medifast's strategic focus on financial recovery and stabilization.
Citadel reports 6.5% stake in MEDIFAST (MED) in joint Schedule 13G
Entities affiliated with Citadel and Kenneth Griffin have jointly filed a Schedule 13G, disclosing a 6.5% beneficial ownership stake in MEDIFAST (MED). The filing indicates that Citadel entities and Kenneth Griffin may be deemed to beneficially own 715,910 shares of Common Stock, representing 6.5% of the class based on 11,031,693 outstanding shares as of March 23, 2026. The reported ownership includes shared voting and dispositive power rather than sole control, with Citadel Securities LLC reporting 712,864 shares.
MED | Medifast, Inc. Financials - Income Statement
This page provides financial information for Medifast, Inc. (MED), focusing on its income statement and other related financial data. It also includes details on congressional trading, insider trading activity, institutional ownership, corporate lobbying, and analyst ratings for MED. The article highlights Medifast's business model as a health and wellness company known for its OPTAVIA solution.
